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ABSTRACT
Our objective was to compare the activity ceftazidime-avibactam (C/A) and ceftolozane–tazobactam
(C/T) against multidrug (including carbapenem) resistant Pseudomonas aeruginosa clinical isolates
collected from six diagnostic centers in Hungary and to reveal the genetic background of their carba-
penem resistance.
Two hundred and fifty consecutive, non-duplicate, carbapenem-resistant multidrug resistant
(MDR) P. aeruginosa isolates were collected in 2017. Minimal inhibitory concentration values of cef-
tazidime, cefepime, piperacillin/tazobactam, C/A and C/T were determined by broth microdilution
method and gradient diffusion test. Carbapenem inactivation method (CIM) test was performed on all
isolates. Carbapenemase-encoding blaVIM, blaIMP, blaKPC, blaOXA-48-like and blaNDM genes were iden-
tified by multiplex PCR.
Of the isolates tested, 33.6% and 32.4% showed resistance to C/A and C/T, respectively. According
to the CIM test results, 26% of the isolates were classified as carbapenemase producers. The suscep-
tibility of P. aeruginosa isolates to C/A and C/T without carbapenemase production was 89% and 91%,
respectively. Of the CIM-positive isolates, 80% were positive for blaVIM and 11% for blaNDM. The
prevalence of Verona integron-encoded metallo-beta-lactamase (VIM)-type carbapenemase was 20.8%.
NDM was present in 2.8% of the isolates.
Although the rate of carbapenemase-producing P. aeruginosa strains is high, a negative CIM result
indicates that either C/A or C/T could be effective even if carbapenem resistance has been observed.
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INTRODUCTION
Pseudomonas aeruginosa is a Gram-negative bacterial pathogen that is an important cause of
multidrug-resistant healthcare-associated infections [1]. P. aeruginosa has recently shown an
increasing resistance rate to carbapenems, making treatment more challenging [2–4]. To treat
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carbapenem-resistant P. aeruginosa, two new combinations
of b-lactams with b-lactamase-inhibitors have recently
become commercially available. Ceftazidime (CAZ), an
older third generation cephalosporin, has been re-issued in
combination with the new broad-spectrum b-lactamase in-
hibitor avibactam in 2015 [5, 6]. Ceftolozane, a novel fifth
generation cephalosporin, was issued in combination with
the older b-lactamase inhibitor tazobactam in late 2014 [7].
Both ceftazidime-avibactam (C/A) and ceftolozane–tazo-
bactam (C/T) have been shown to successfully treat most
carbapenem-resistant P. aeruginosa infections [8–10].
There are several advantages of the novel drugs avi-
bactam and ceftolozane compared to their older counter-
parts. Both tazobactam and avibactam inhibit serin b-
lactamases. While tazobactam is ineffective against many
known b-lactamases and carbapenemases, avibactam is
active against ESBL and AmpC b-lactamases as well as the
Klebsiella pneumoniae carbapenemase (KPC) and OXA-48
carbapenemases [11]. Additionally, avibactam binds to b-
lactamases reversibly, allowing it to be recycled and inhibit
additional b-lactamases [11]. Likewise, when comparing
ceftolozane to CAZ, the newer drug ceftolozane has further
advantages including higher penetration despite porin
downregulation, resistance to efflux pump mechanisms,
and greater stability to AmpC b-lactamases [11–13].
Regardless of the advantages of the new drugs avibactam
and ceftolozane, neither are effective against most P. aeru-
ginosa strains that produce carbapenemases. [3, 13, 14]. The
metallo-b-lactamase (MBL)-type carbapenemase P. aerugi-
nosa strains are particularly concerning due to their strong
capacity to hydrolyze b-lactams, co-resistance with other
antimicrobial classes, and their accelerating spread world-
wide [3, 13–17]. Early laboratory detection of carbapene-
mase production can be critical to provide optimal
antimicrobial treatment. Carbapenemase production can be
evaluated by the carbapenem inactivation method (CIM), a
simple and cost-effective test [18]. Multiplex PCR is used to
detect various carbapenemase-encoding genes, including the
carbapenem-hydrolyzing class D b-lactamase OXA-48,
Ambler class A KPC, and the MBL Verona integron-enco-
ded metallo-beta-lactamase (VIM), IMP, and NDM [19].
The purpose of the study was threefold. First, we evaluated
the susceptibility of carbapenem-resistant multidrug resistant
(MDR) P. aeruginosa isolates to C/A and C/T. Second, we
examined the genotype of carbapenemase-producing P. aer-
uginosa isolates and how carbapenemase production in-
fluences C/A and C/T resistance. Third, we sought to
determine the clinical value of the CIM test as a tool for
determining antibiotic susceptibility.
MATERIALS AND METHODS
A total of 250 consecutive, non-duplicate, multidrug
(including carbapenem) resistant P. aeruginosa isolates from
six diagnostic centers in Hungary (representing the country)
were collected in 2017. The criteria of collection were
multidrug resistance (non-susceptible to at least one agent in
≥3 antimicrobial groups: aminoglycosides (testing genta-
mycin, tobramycin, amikacin), fluoroquinolones (testing
ciprofloxacin and levofloxacin) and b-lactams (testing CAZ,
cefepime (FEP), piperacillin/tazobactam (P/T)), including
both meropenem and imipenem resistance, based on disk
diffusion method according to EUCAST guidelines [20].
Bacterial identification was performed by MALDI-TOF MS.
Susceptibility patterns of CAZ, FEP and P/T were also
tested by broth microdilution method [21]. Minimal inhib-
itory concentration (MIC) values of C/A and C/T were
determined by gradient diffusion test (Liofilchem). Escher-
ichia coli ATCC 25922 and P. aeruginosa American Tissue
Type Collection (ATCC) 27853 were used as control strains.
CIM test was performed on all isolates in the manner
described by Zwalul [18]. Briefly, a full 10 mL inoculation
loop of bacteria was suspended in 400 mL water, then a disk
containing 10 mg meropenem was immersed in the sus-
pension and incubated for 3 hours at 35 8C. After incuba-
tion, the disk was removed from the suspension and placed
on a Mueller-Hinton agar plate that had already been
inoculated with ATCC 29522 E. coli indicator strain. The
plate was subsequently incubated at 35 8C overnight. Isolates
showing an inhibition zone ≤15 mm around the mer-
openem disk were defined as carbapenemase producers [2].
The carbapenemase-encoding genes blaVIM, blaIMP, blaKPC,
blaOXA-48-like and blaNDM were tested among CIM-positive
isolates by multiplex PCR according to Poirel et al. [19].
RESULTS
Results of antimicrobial susceptibility testing are summa-
rized in Table 1. Of the 250 tested isolates, 33.6% (n 5 84)
were resistant to C/A and 32.4% (n 5 81) were resistant to
C/T. Most of the isolates (97%, n 5 243) showed categorical
Table 1. MIC values and resistance rates of investigated b-lactams among carbapenem-resistant Pseudomonas aeruginosa isolates
Antimicrobial agent MIC range (mg/L) MIC50 (mg/L) MIC90 (mg/L)
EUCAST susceptibility
breakpoint (mg/L) Resistance (%)
Ceftazidime–avibactam 1 to ≥256 8 ≥256 8 33.6
Ceftolozane-tazobactam 0.5 to ≥256 4 ≥256 4 32.4
Ceftazidime 2 to >256 64 256 8 93.2
Cefepime 8 to >256 64 >256 8 99.2
Piperacillin-tazobactam 4 to >256 128 >256 16 97.2
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agreement to C/A and C/T. Two isolates showed suscepti-
bility to C/A but resistance to C/T, and five isolates showed
resistance to C/A yet susceptibility to C/T. All strains with
discordant susceptibility results were retested to minimize
methodical error. Distribution of MIC values of C/A and C/
T are shown in Fig. 1.
Only 17 of the 250 isolates (7%) were susceptible to CAZ
without avibactam. Sixty-four percent of the CAZ-resistant
isolates (149/233) retained susceptibility to C/A. Only seven
(2.8%) strains showed susceptibility to P/T. All of these sus-
ceptible isolates also showed susceptibility to C/T. Of the 243
P/T resistant isolates, 162 (66%) showed susceptibility to C/T.
Sixty-five of the 250 isolates were classified as carbape-
nemase producers according to the CIM test results. All but
one CIM-positive isolate showed resistance to both C/A and
C/T. CIM positivity showed strong correlation with resis-
tance to both tested cephalosporin/b-lactamase inhibitor
combinations. For both C/A and C/T resistance, the CIM
test showed a positive predictive value (PPV) of 98% and a
specificity of 99%. For C/A resistance, the CIM test showed a
sensitivity of 76% and negative predictive value (NPV) of
89%. For C/T resistance alone, the CIM test showed a
sensitivity of 79% and NPV of 91%.
Of the 65 isolates that tested positive in the CIM
test, 80% (n 5 52) were positive for the VIM gene and 11%
(n 5 7) were positive for the NDM gene. All seven isolates
found to contain NDM genes were resistant to C/A and C/T,
with minimal inhibitory concentrations ≥256 mg/L. All
VIM-positive isolates conferred resistance to C/A and C/T
with MIC values 16 to ≥256 mg/L and ≥256 mg/L,
respectively. The remaining six CIM-positive isolates did not
contain any of the genes tested.
DISCUSSION
In this study the susceptibility rates of carbapenem-resis-
tant MDR P. aeruginosa to both C/A and C/T are com-
parable to one another, at 66.4% and 67.6% respectively.
Of note, other studies reported higher susceptibility to C/T
than C/A: Grupper et al. observed 91% C/T susceptibility
and 81% C/A susceptibility among 290 meropenem-non-
susceptible isolates from 34 hospitals in the United States
in 2013 and 2014 [22]. Humphries et al. observed 61.8%
susceptibility to C/A and 72.5% susceptibility to C/T in a
similar study of b-lactam resistant P. aeruginosa, with
36.4% of C/A-resistant isolates still susceptible to C/T [7].
Ceftolozane is believed to have several advantages over
CAZ regarding resistance: greater affinity for penicillin-
binding proteins produced by P. aeruginosa, better mem-
brane permeability, greater stability against AmpC b-lac-
tamases, and more potency against P. aeruginosa isolates
with up-regulated efflux pumps and loss of porins [9, 12].
Our results support only modest advantages of C/T over
C/A. Of the tested 250 isolates just five were susceptible to
C/T but not to C/A. Additionally, two isolates were sus-
ceptible to C/A but not to C/T. The previously-mentioned
advantageous mechanisms of ceftolozane may be respon-
sible for the strains that were susceptible to C/T but
resistant to C/A. For the strains that were susceptible to C/
A but resistant to C/T, differences between the carbape-
nemase inhibitor potency of avibactam and tazobactam
may have an impact. The susceptibility to CAZ among our
isolates increased from 7% to 66% when avibactam is
included, indicating strong potency of avibactam as a b-
lactamase inhibitor. We do not have a similar comparison
to make with ceftolozane and tazobactam, but P/T showed
an even higher rate of resistance than that was seen in CAZ
without a b-lactamase inhibitor. Prior use of tazobactam as
a b-lactamase inhibitor has allowed several decades for
resistance mechanisms to develop, and this may be a
contributing factor to resistance to C/T but not C/A.
The potency of C/A and C/T in P. aeruginosa isolates
that do not produce some form of carbapenemase is
consistent with previous studies [8]. For strains that did
not produce carbapenemase (tested negative in the CIM
test), susceptibility to C/A and to C/T was 89% and 91%,
respectively. This susceptibility rate among CIM-negative
isolates is much higher than the overall susceptibility rates
of 66–68%. Buehrle et al. reported similar patterns of 92%
susceptibility to both C/A and C/T among 38 meropenem-
resistant P. aeruginosa isolates without carbapenemase
production [8]. This indicates that the CIM test could be
valuable in routine clinical antibiotic susceptibility testing.
CIM is a simple and low-cost test that can be completed in
less than one day [2, 18]. A negative CIM result indicates
that either C/A or C/T would likely be effective treatments,
even if carbapenem resistance has already been estab-
lished.
The rate of spread of the VIM-type MBL is alarming,
appearing in 20.8% of the total number of isolates. The
presence of the NDM in 2.8% of our P. aeruginosa isolates
is also a cause for concern, since the first blaNDM-1 positive
P. aeruginosa in Hungary was reported in 2019 [23]. While
the sample size is small (n 5 7), the isolates expressing
NDM showed the strongest possible resistance to all b-
lactam antibiotics that were tested. The rapid spread of
VIM and NDM carbapenemases among many species of
Gram-negative bacteria over the last decade could soon end
many of the currently-available antimicrobial therapeutic
options, including the newer treatments C/A and C/T.
Only more toxic antimicrobials such as colistin appear to
Figure 1. Distribution of MIC values of ceftazidime-avibactam and
ceftolozane–tazobactam among carbapenem- and multidrug-resis-
tant Pseudomonas aeruginosa isolates, gray column: C/A: ceftazi-
dime-avibactam, black column: C/T: ceftolozane–tazobactam
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maintain potency against these multidrug or extensively
drug-resistant P. aeruginosa isolates, although resistance
against even these antimicrobial classes is beginning to
develop [15, 17].
Although the rate of carbapenemase-producing P. aer-
uginosa strains is high according to our study, a negative
CIM result indicates that either C/A or C/T could be
effective even if carbapenem resistance has been observed.
As P. aeruginosa is known to quickly gain antibiotic resis-
tance via several mechanisms besides carbapenemase pro-
duction, further testing of susceptibility patterns to C/A and
C/T should be performed regularly. As the rate of resistance
rises, there is an urgent need to develop new and safe classes
of antimicrobial therapy. Until novel agents have been
developed, strong infection control measurements are
essential to protect patients from MDR P. aeruginosa in-
fections.
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